Phase I clinical trial to assess safety and immunogenicity of an MVA-based influenza H5 vaccine in healthy adults
Completed
- Conditions
- fluInfluenza10047438
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 27
Inclusion Criteria
• 18-35 years of age
• Female volunteers must acquire an acceptable form of contraception during the study period and to have a negative pregnancy test on the days of immunization.
• Refrain from blood donation during the study period
• Written informed consent
• Able and willing to comply with all study requirements
Exclusion Criteria
• Pregnancy or lactation
• Acute or chronic illness
• Known allergy to eggs, egg products or chicken protein
• Previous immunization with a recombinant MVA
• Previous immunization with an influenza A/H5N1 vaccine
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie MVA-based H5 vaccine immunogenicity in healthy adults?
How does MVA-based H5 vaccine compare to standard influenza vaccines in clinical trials?
Which biomarkers correlate with immune response to MVA-H5 vaccination in phase I studies?
What adverse events are associated with MVA-based influenza vaccines in adult populations?
Are there combination strategies involving MVA-H5 vaccines for enhanced pandemic influenza protection?